NEW YORK (GenomeWeb) – Cowen said today that it has upgraded its rating on Hologic's shares to Outperform from Market Perform, based in part on the investment bank's expectation of "resilient" mid-single-digit or greater than high-single-digit revenue growth for Hologic's molecular diagnostics business.

In a research note, analyst Doug Schenkel said that Cowen's revenue growth expectations were also driven by expected sales for Hologic's new products, and continued mid-single-digit or high-single-digit growth for its surgical business.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.